Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will ...

Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was ...

Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin ...

The trial, conducted in the United Kingdom, found that a procalcitonin-guided algorithm didn't reduce IV antibiotic duration ...

A study published last year highlighted innovative modifications to vancomycin—a go-to antibiotic for infections like enterococcus, which can cause urinary tract and bloodstream infections.

Immuron Limited (IMRN), an Australian-based biopharmaceutical company, Wednesday, announced a new research collaboration with Monash ...

based on the results of the earlier TARGET study which showed non-inferiority for the drug compared to vancomycin plus aztreonam. If it gets a green light, it will be the first antibiotic in the ...

BACKGROUND/AIMS To study the intravitreal antibiotic concentrations and the efficacy of an intravitreal dosing regimen to treat patients with postoperative bacterial ...

Immuron (IMRN) announced a new research collaboration agreement with Monash University. The major objective of this research collaboration is ...